Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Assets: 2015-2025

Historic Assets for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $288.3 million.

  • Voyager Therapeutics' Assets fell 32.33% to $288.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.3 million, marking a year-over-year decrease of 32.33%. This contributed to the annual value of $393.1 million for FY2024, which is 11.89% up from last year.
  • Per Voyager Therapeutics' latest filing, its Assets stood at $288.3 million for Q3 2025, which was down 10.49% from $322.1 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Assets peaked at $469.6 million during Q1 2024, and registered a low of $159.4 million during Q4 2022.
  • Moreover, its 3-year median value for Assets was $351.3 million (2023), whereas its average is $362.4 million.
  • Per our database at Business Quant, Voyager Therapeutics' Assets skyrocketed by 120.44% in 2023 and then tumbled by 32.33% in 2025.
  • Voyager Therapeutics' Assets (Quarterly) stood at $193.9 million in 2021, then dropped by 17.80% to $159.4 million in 2022, then surged by 120.44% to $351.3 million in 2023, then increased by 11.89% to $393.1 million in 2024, then tumbled by 32.33% to $288.3 million in 2025.
  • Its Assets stands at $288.3 million for Q3 2025, versus $322.1 million for Q2 2025 and $353.2 million for Q1 2025.